Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anluohuaxian for Pulmonary Fibrosis in COVID-19 Rehabilitation Patients
NCT04334265Unknown
- Sponsor
- Peking University First Hospital
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
Randomised, open-label trial of anluohuaxian in pulmonary fibrosis (PF) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: Changes in high-resolution computer tomography of the lung at 3 months and Change in 6-minute walking distance at 3 months. Status: unknown.
02
Drugs
anluohuaxian
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04334265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334265.